Germline Gene Editing for Sickle Cell Disease

Click to increase image sizeClick to decrease image size

This article refers to:

Revising, Correcting, and Transferring Genes

DISCLOSURE STATEMENT

AS is the principal investigator of a clinical trial for somatic gene therapy of sickle cell disease sponsored by Vertex Pharmaceuticals/CRISPR Therapeutics. The sponsor provides funding for the clinical trial which includes salary support paid to his institution. This is not related in any way to this work product. AS also has research collaboration with Novartis on their sickle cell gene therapy clinical trial for which AS is not financially compensated in any way.